Photo credit: www.sciencedaily.com

Breakthrough in Prenatal Care: Identifying Treatable Genetic Disorders

A collaborative study involving researchers from Mass General Brigham, Harvard Medical School, and Duke University School of Medicine has revealed a significant advancement in prenatal care, identifying nearly 300 genetic disorders that can be addressed before or just after a baby is born. This newly established “treatable fetal findings list” has the potential to significantly enhance the diagnosing of genetic conditions during pregnancy and broaden the treatment options for affected fetuses. The findings from this research have been published in the American Journal of Human Genetics.

Lead researcher Dr. Nina Gold, who directs Prenatal Medical Genetics at Massachusetts General Hospital, emphasized the critical void in current prenatal care and the necessity to define genetic disorders that can be effectively treated during pregnancy. “These conditions are actionable—meaning that, with the right diagnostic information, early intervention can be implemented, leading to improved health outcomes,” said Gold.

Over the last ten years, genomic sequencing has emerged as an essential tool in enhancing prenatal diagnoses. Through genomic tests, especially when combined with family health histories, researchers can pinpoint genetic anomalies linked to ultrasound findings. Additionally, these tests can identify incidental but significant conditions that could pose risks to the fetus or newborn, such as treatable heart or gastrointestinal disorders. This research team aims to compile a list of such treatable conditions, thus allowing parents the option to receive vital information regarding their unborn child’s health.

As part of their study, the authors conducted an extensive literature review, concluding with a total of 296 genetic conditions recognized for having available treatments, ranging from those with emerging therapeutic options for fetuses to others that require urgent postnatal intervention to avert severe complications. The authors further stress that early detection of these conditions can significantly decrease morbidity and mortality rates, opening up significant opportunities for intervention for families.

Dr. Jennifer Cohen, the study’s lead author and a medical geneticist at Duke University Hospital, remarked, “One of our primary objectives is to broaden the range of options available to families during pregnancy. This list of genetic conditions is intended to facilitate early interventions that, in some situations, might alter the anticipated progression of the disease.”

Nonetheless, the study acknowledges several challenges associated with this initiative. The researchers pointed out ethical dilemmas that may arise and recognized that the volume of information could overwhelm expectant parents. They stressed the need for engagement among medical geneticists, obstetricians, and ethicists to carefully navigate these complex scenarios.

Gold highlighted the goal of their research, stating, “While our targeted list of treatable fetal findings strives to enhance patient care, we are acutely aware of the challenges faced by healthcare providers, genetic counselors, and patients in dealing with new health information during pregnancy or shortly after birth. Collaboration as a care team is essential to empower patients and provide them with clear and comprehensible information.”

Source
www.sciencedaily.com